Study on Elranatamab for Treating Multiple Myeloma That Has Returned After Previous Treatments

Sponsor: Pfizer

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06152575

Provider View

This clinical trial is testing a new medicine called elranatamab for people with multiple myeloma, a type of cancer, that has come back after other treatments. The study will compare elranatamab to other standard treatments to see which works better.

Patient Parameters

Program Overview

The purpose of this study is to learn about a new medicine called elranatamab for treating multiple myeloma (MM), a type of cancer. The study will compare elranatamab to other standard treatments to see which is more effective. Participants must be 18 or older, have MM, and have tried other treatments that didn't work or the cancer has returned. Half of the participants will receive elranatamab, while the other half will receive a combination of 2 to 3 standard medicines chosen by the study doctor. Elranatamab is given as a shot under the skin, while the combination therapy may be taken by mouth or given as a shot or through a vein. Participants will continue treatment until their MM stops responding, with regular check-ups at the clinic. The study will help determine the safety and effectiveness of elranatamab compared to other treatments.

Eligibility Criteria

Inclusion Criteria

  • Have been diagnosed with multiple myeloma and have received 1 to 4 previous treatments, including an anti-CD38 antibody and lenalidomide.
  • Show signs that the disease is getting worse or not responding to the last treatment.
  • Have measurable disease, such as specific levels of proteins in the blood or urine.
  • Have certain lab test results within a specified range.
  • Have an ECOG performance status of 2 or less, meaning they are able to carry out all self-care but unable to carry out any work activities.
  • Not be pregnant or breastfeeding and agree to use contraception.

Exclusion Criteria

  • Have smoldering multiple myeloma, plasma cell leukemia, amyloidosis, or POEMS syndrome.
  • Have known involvement of the central nervous system by the cancer.
  • Have had a stem cell transplant within 12 weeks before joining the study or have active graft versus host disease.
  • Have any active, uncontrolled infections.
  • Have had another active cancer within the last 3 years, except for certain skin cancers or carcinoma in situ.
  • Have previously been treated with BCMA-directed therapy or CD3-redirecting therapy.
  • Be unable to receive the therapy chosen by the investigator.
  • Have received a live vaccine within 4 weeks before the first dose of the study treatment.
  • Have taken an investigational drug or vaccine within 30 days before the first dose of the study treatment.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.